English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
Add to Basket
  Local TagsRelease HistoryDetailsSummary

Released
Journal Article

Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation.

MPS-Authors
/persons/resource/persons219048

Caldarelli,  Antonio
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

/persons/resource/persons289574

Rost,  Fabian
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

/persons/resource/persons285724

Rodriguez-Muela,  Natalia
Max Planck Institute for Molecular Cell Biology and Genetics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available
Citation

Grass, T., Dokuzluoglu, Z., Buchner, F., Rosignol, I., Thomas, J., Caldarelli, A., et al. (2024). Isogenic patient-derived organoids reveal early neurodevelopmental defects in spinal muscular atrophy initiation. Cell reports. Medicine, 5(8): 101659. doi:10.1016/j.xcrm.2024.101659.


Cite as: https://hdl.handle.net/21.11116/0000-0010-D54F-6
Abstract
Whether neurodevelopmental defects underlie postnatal neuronal death in neurodegeneration is an intriguing hypothesis only recently explored. Here, we focus on spinal muscular atrophy (SMA), a neuromuscular disorder caused by reduced survival of motor neuron (SMN) protein levels leading to spinal motor neuron (MN) loss and muscle wasting. Using the first isogenic patient-derived induced pluripotent stem cell (iPSC) model and a spinal cord organoid (SCO) system, we show that SMA SCOs exhibit abnormal morphological development, reduced expression of early neural progenitor markers, and accelerated expression of MN progenitor and MN markers. Longitudinal single-cell RNA sequencing reveals marked defects in neural stem cell specification and fewer MNs, favoring mesodermal progenitors and muscle cells, a bias also seen in early SMA mouse embryos. Surprisingly, SMN2-to-SMN1 conversion does not fully reverse these developmental abnormalities. These suggest that early neurodevelopmental defects may underlie later MN degeneration, indicating that postnatal SMN-increasing interventions might not completely amend SMA pathology in all patients.